Pemvidutide resolved metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, without worsening liver scarring (fibrosis) for more than half of people…
News
BILIARY ATRESIA
NewsPrenatal ultrasound AI analysis IDs biliary atresia before birth in study
Biliary atresia, a rare liver disease affecting infants, may be diagnosed before birth using a novel artificial intelligence (AI) method that analyzes prenatal ultrasound…
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy of bemnifosbuvir and ruzasvir in people with chronic…
CHOLANGITIS
NewsEMA to review linerixibat for itch in primary biliary cholangitis
The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).
CHOLESTASIS
NewsResearchers develop mutation database, mouse model for PFIC2
Researchers have developed a database of all ABCB11 mutations known to cause progressive familial intrahepatic cholestasis type 2 (PFIC2) and a new mouse model…
FATTY LIVER DISEASE
NewsEMA committee supports Rezdiffra’s OK for fatty liver disease MASH
A committee of the European Medicines Agency (EMA) has granted a positive opinion to Rezdiffra (resmetirom) to treat some people with metabolic dysfunction-associated steatohepatitis (MASH),…
ALAGILLE SYNDROME
NewsTargeted chemotherapy effective for HCC in woman with Alagille
A targeted treatment called transarterial chemoembolization (TACE) successfully helped control hepatocellular carcinoma (HCC), the most common type of liver cancer, in a young woman with…
CHOLANGITIS
NewsMononucleosis linked to higher risk of developing PSC: Study
Note: This story was updated Aug. 8, 2025, to correct that infectious mononucleosis was linked to a 4.6 times higher risk of future PSC, not  a…
CHOLESTASIS
NewsNew MYO5B gene mutation detected in man with PFIC type 10
A combination of two mutations in the MYO5B gene, including one that has not been previously reported, was the likely cause of a mild form…
FATTY LIVER DISEASE
NewsDiabetes drug dapagliflozin shows benefits for MASH in Phase 3 trial
Daily treatment with the diabetes medication dapagliflozin eased disease severity for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease,…
Recent Posts
- Breastmilk helps babies recover after Kasai surgery, study shows
- Bepirovirsen under review in Europe as a treatment for chronic hepatitis B
- ALF marks Donate Life Month in April with focus on living liver donors
- Why we might cancel a doctor’s appointment (and why we shouldn’t)
- Inflammation markers may predict fetal risk in ICP: Study